Stories
NPPA Caps Trade Margins for 137 Non-Scheduled Anti-Cancer Drugs to Slash Prices by Up to 70 Percent
N
News18•17-10-2026, 20:00
NPPA Caps Trade Margins for 137 Non-Scheduled Anti-Cancer Drugs to Slash Prices by Up to 70 Percent
- •The National Pharmaceutical Pricing Authority has capped trade margins at 30 percent for 137 non-scheduled anti-cancer drugs to make cancer treatment more affordable.
- •The price intervention is expected to reduce the Maximum Retail Price of these critical medicines by up to 70 percent depending on existing price structures.
- •This move builds upon the 2019 pilot TMR exercise and follows recommendations from an Expert Committee comprising leading oncologists and medical specialists.
- •Manufacturers must inform NPPA of revised prices within 7 days, with new prices taking effect from November 9 across all retailers and hospitals.
- •State Drug Controllers and manufacturers must ensure compliance, maintain steady production levels, and prevent artificial market shortages.
Key Questions Answered
The National Pharmaceutical Pricing Authority (NPPA) has capped trade margins at 30% of the Maximum Retail Price (MRP) for 137 identified non-scheduled anti-cancer drugs.
The intervention is expected to lower the MRP of these non-scheduled anti-cancer drugs by up to 70%, depending on their existing price structures.
The revised prices become effective from November 9, and all manufacturers, retailers, and hospitals must charge and display these reduced prices. Consumers can check the updated prices via the NPPA website or the Pharma Sahi Daam app.
